This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berrizbietia, M.
Right arrow Articles by Ward, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berrizbietia, M.
Right arrow Articles by Ward, B. J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2004, p. 1766-1769, Vol. 42, No. 4
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.4.1766-1769.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Development and Comparison of Enzyme Immunoassays for Diagnosis of Chagas' Disease Using Fixed Forms of Trypanosoma cruzi (Epimastigotes, Amastigotes, and Trypomastigotes) and Assessment of Antigen Stability for the Three Assays

Mariolga Berrizbietia,1,2 Momar Ndao,1 Marcelo Gottschalk,2 Alberto Aché,3 Fabio Vásquez,1 Sonia Lacouture,2 Mehudy Medina,3 and Brian J. Ward1*

National Reference Centre for Parasitology, Montreal General Hospital, McGill University,1 Faculté de Medicine Vétérinaire, Université de Montréal, Quebec, Canada,2 Ministerio de Salud y Desarrollo Social, Caracas, Venezuela3

Received 15 August 2003/ Returned for modification 2 November 2003/ Accepted 9 January 2004

Three enzyme immunoassays (EIAs) for diagnosis of Chagas' disease were developed with fixed forms of Trypanosoma cruzi using a panel of 435 sera from the following groups: Venezuelan subjects positive by immunofluorescence (n = 70), Venezuelan healthy controls (n = 85), healthy Canadians (n = 166), and subjects with other parasitic diseases (n = 114). All assays achieved 100% sensitivity and reasonable specificity for amastigotes (97.6%), epimastigotes (98.3%), and trypomastigotes (99.3%). The fixed-trypomastigote assay was stable over 4 months at 4°C and room temperature. These data suggest that a fixed-trypomastigote EIA may be a suitable candidate for blood bank screening.

* Corresponding author. Mailing address: McGill Center for Tropical Diseases, Montreal General Hospital, Room D7-153, Montreal, Quebec H3G IA4, Canada. Phone: (514) 937-6011, ext. 428 10. Fax: (514) 934-8347. E-mail: brian.ward{at}mcgill.ca.

Journal of Clinical Microbiology, April 2004, p. 1766-1769, Vol. 42, No. 4
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.4.1766-1769.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Berrizbeitia, M., Ndao, M., Bubis, J., Gottschalk, M., Ache, A., Lacouture, S., Medina, M., Ward, B. J. (2006). Purified Excreted-Secreted Antigens from Trypanosoma cruzi Trypomastigotes as Tools for Diagnosis of Chagas' Disease. J. Clin. Microbiol. 44: 291-296 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»